Parexel Announces Acquisition of Leading Pharmacology Modeling & Analytics Modeling Firm Model Answers
Summary
BOSTON and DURHAM, N.C. and BRISBANE, Australia , Feb. 20, 2020 (GLOBE NEWSWIRE) -- , a leading provider of solutions to accelerate the development and delivery of innovative new therapies to improve world health, from Clinical through Commercialization, today announced it has completed the acquisition of Model Answers, a consultancy firm based in Brisbane, Queensland, Australia. “Modeling and simulation have quickly become a valuable part of the drug development process, helping to reduce risk and increase the likelihood of success by predicting outcomes that can result in a more informed trial design,” said Sy Pretorius, M.D., Executive Vice President and Chief Medical & Scientific Officer. The company has significant experience developing preclinical PK and PD models for effectiveness and neutropenia, scaling to first-in-human studies, then supporting Phase I through to NDA submission. We do this through a suite of services that help life science and biopharmaceutical customers across the globe transform scientific discoveries into new treatments for patients. From clinical trials to regulatory and consulting services to commercial and market access, our therapeutic, technical and functional ability is underpinned by a deep conviction in what we do.